StreetAlpha.app
Home › Stocks › NTLA

Intellia Therapeutics, Inc. (NTLA)

Healthcare
$10.00
▲ +5.04%
LAST CLOSE · NOV 20

Intellia develops CRISPR gene editing treatments for severe diseases, with lead candidates in late stage clinical trials. It last closed at $10.00 on Nov 20, up 5.04% on the day. The next earnings report for NTLA is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, NTLA reported EPS of -$0.91 on revenue of $7.2M, with revenue down 48.0% from a year ago. Over its last 8 reports the stock moved an average of 7.2% the session after earnings. Over the last 12 months NTLA insiders bought $1.4M of stock on the open market and sold $2.3M, according to SEC Form 4 filings.

AI Auto Pilots
Is NTLA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold NTLA.

Key Stats

Last 12 months
Results
Revenue
$52.9M
−8.1% vs a year ago
Net income
−$426.1M
−805.7% margin
EPS (diluted)
−$3.35
Free cash flow
−$358.1M
−677.1% margin
Valuation
Market cap
$1.4B
140.4M shares
P/E
–
No P/E while losing money
Price to sales
26.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$156.1M
At Sep 30
Debt
$73.7M
At Sep 30
Shareholder equity
$613.1M
Shares outstanding
140.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $33.1M$33.1MFY2021FY2022: $52.1M$52.1MFY2022FY2023: $36.3M$36.3MFY2023FY2024: $57.9M$57.9MFY2024FY2025: $67.7M$67.7MFY2025

From NTLA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.91
Quarter ended Sep 2026
Year ago EPS
-$0.92
Same quarter last year
Revenue
$7.2M
−48.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.26Dec '24Mar 2025: -$1.10Mar '25Jun 2025: -$0.98Jun '25Sep 2025: -$0.92Sep '25Dec 2025: -$0.82Dec '25Mar 2026: -$0.81Mar '26Jun 2026: -$0.80Jun '26Sep 2026: -$0.91Sep '26Latest -$0.91
Revenue by quarter
Dec 2024: $12.9MDec '24Mar 2025: $16.6MMar '25Jun 2025: $14.2MJun '25Sep 2025: $13.8MSep '25Dec 2025: $23.0MDec '25Mar 2026: $15.0MMar '26Jun 2026: $7.7MJun '26Sep 2026: $7.2MSep '26Latest $7.2M
How NTLA moved after its last 8 reports
Average move the session after a report ±7.2%
Nov 5, 2026Time not announced−9.8%
Aug 6, 2026Time not announced+2.5%
Apr 30, 2026After the close−1.6%
Feb 26, 2026Time not announced+6.4%
Nov 6, 2025After the close−22.7%
Aug 7, 2025Time not announced+0.8%
May 8, 2025Time not announced+13.6%
Feb 27, 2025Time not announced+0.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on NTLAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on NTLA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on NTLA

Technical Analysis

NTLA · as of the Nov 20 close · updated each morning
Downtrend

The stock is 12% below its 20 day and 17% below its 50 day average. It is 29% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot at $9.90, and the nearest resistance the Pivot R1 at $10.50.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 8.5%/day
Key levels
$18.4852 week high+84.8%
$12.89200 day average+28.9%
$12.11100 day average+21.1%
$11.99Swing high (Oct 20)+19.9%
$11.6750 day average+16.7%
$11.2420 day average+12.4%
$10.50Pivot R1+5.0%
$10.00Last close
$9.90Pivot−1.0%
$9.40Pivot S1−6.0%
$7.9552 week low−20.5%
Indicators
RSI (14)40.74Middle of its rangeNeutral
MACD-0.60Below its signal lineBearish
Stochastic14.2Near the bottom of its rangeOversold
ADX (14)15.4No clear trend
Williams %R-73.1Oversold below −80, overbought above −20Neutral
CCI (20)-102.4Oversold below −100, overbought above 100Oversold
Rate of change−11.9%Change over 10 sessionsBearish
ATR (14)$0.85Typical daily range, 8.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NTLA

What happened before

See how NTLA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow NTLA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How NTLA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for NTLAHow many large options trades hit NTLA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

NTLA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●154 buying vs 140 selling
  • ▼Held by funds -6.0 pts
  • ▼Funds holding -16
  • ▼Superinvestors: 1 added, 5 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding314330−4.8%
In funds' top 1012−50.0%
Held by funds96.6%102.6%−6.0 pts
New / increased35 / 11952 / 139−19.4%
Reduced / sold out90 / 5083 / 29+25.0%
Put/call ratio0.200.19+0.4%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NTLA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

NTLA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$1.4M1 buy · 1 insider
Sold$2.3M16 sales · 7 insiders
58% of the selling was under pre-arranged trading plans.
2025-12 sold $836K2026-01 bought $1.4M2026-01 sold $772K2026-03 sold $25K2026-07 sold $220K2026-08 sold $287K2026-10 sold $23K2026-11 sold $108KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 2John M LeonardPresident and CEOSale plan9,000$11.99$108K
Oct 2Michael P DubeVP, Chief Accounting OfficerSale1,864$12.43$23K
Aug 21John M LeonardPresident and CEOSale plan22,675$12.65$287K
Jul 22Edward J Dulac IIIEvp, CFOSale8,111$11.25$91K
Jul 2Edward J Dulac IIIEvp, CFOSale plan4,677$18.00$84K
Jul 1Michael P DubeVP, Chief Accounting OfficerSale2,641$16.78$44K
Every insider buy and sale for NTLA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See NTLA insider trades →

From SEC Form 4 filings by NTLA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NTLA is in one of them and how their past NTLA trades turned out.

NTLA in the AI portfolios
Loading…

NTLA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NTLA in an article yet. Here's the latest on the wider market.

NTLA in the news

NTLA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Sep 5
Who traded NTLA · since 2017
Latest 5 filings of 16
$1K – $15KTraded Aug 25, 2023Filed Sep 5, 2023
$1K – $15KTraded May 22, 2023Filed Jun 30, 2023
$15K – $50KTraded Feb 28, 2022Filed Mar 3, 2022
$1K – $15KTraded Oct 29, 2021Filed Oct 30, 2021
$1K – $15KTraded Sep 20, 2021Filed Oct 1, 2021
PersonTypeAmountTradedFiledDelay
Tom CarperD · DESell$1K – $15KAug 25, 2023Sep 5, 202311 d
Tom CarperD · DEBuy$1K – $15KMay 22, 2023Jun 30, 202339 d
Don BeyerD · VASell$15K – $50KFeb 28, 2022Mar 3, 20223 d
Don BeyerD · VASell$1K – $15KOct 29, 2021Oct 30, 20211 d
Don BeyerD · VASell$1K – $15KSep 20, 2021Oct 1, 202111 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Intellia Therapeutics

Intellia is a biopharmaceutical company based in Cambridge, Massachusetts, that develops treatments using CRISPR gene editing. Its lead candidates are designed to address the underlying cause of rare, severe diseases, including hereditary angioedema and ATTR amyloidosis, and are given as a single intravenous infusion. The company's lead candidates are in late stage clinical trials, and it is preparing for possible commercial launches aimed at patients with these conditions. It also works with partners, such as Regeneron, on additional programs.

Headquarters
Cambridge, MA
Founded
2014